Oral sustained-release cisplatin capsule

Journal of Pharmacy and Pharmacology

Volumn 48, Issue 5, 1996, Pages 474-478

  Houjou, Takeshi ^a   Nakano, Kousuke ^a   Ike, Osamu ^b   Wada, Hiromi ^b   Hitomi, Sigeki ^b   Shinmi, Yuuko ^a   Danno, Noriyuki ^a   Yoshikawa, Yukako ^a   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOMER; CISPLATIN; ETHYL CELLULOSE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RABBIT; SUSTAINED RELEASE PREPARATION;

EID: 0030007541     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1996.tb05957.x     Document Type: Article

References (27)

1. Bin, P., Boddy, A. V, English, M. W., Pearson, D. J., Price, L., Tilby, M. J., Newell, D. R. (1994) The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review. Anticancer Res. 14: 2279-2284
2. Daugaard, G., Abiljaard, U, Holstein-Rathlou, N.-H., Leyssac, P. P., Amtorp, O., Dikhoff, T. G. (1986) Acute effect of cisplatin on renal hemodynamics and tubular function in dog kidneys. Renal Physiol. 9: 308-316
3. Duchene, D., Touchard, F., Peppas, N. A. (1988) Pharmaceutical and medical aspects of bioadhesive systems for drug administration. Drug Dev. Ind. Pharm. 14: 283-318
4. Egorin, M. J., Van Echo, D. A., Tipping, S. J., Olman, E. A., Whitacre, M. Y., Thompson, B. W., Aisner, J. (1984) Pharmacokinetics and dosage reduction of cis-diammine(l ,l-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res. 44: 5432-5438
5. Fish, R. G., Shelley, M. D., Badman, J., Mason, M., Adams, M., Paterson, I. (1994) Platinum accumulation in adult cancer patients receiving cisplatin: plasma and urinary platinum concentrations on first drug exposure. Drug Invest. 7: 175-182
6. Forastiere, A. A., Belliveau, J.F., Goren, M. P., Vogel, W. C., Posner, M. R., O'Leary, G. P. (1988) Pharmacokinetics and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum (II) in head and neck cancer patients. Cancer Res. 48: 3869-3874
7. Gottlieb, J. A., Drewinko, B. (1975) Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother. Rep. 59: 621-628
8. Gu, J-M., Robinson, J. R., Leung, S.-H. S. (1988) Binding of acrylic polymers to mucin/epithelial surfaces: structure-property relationship. Crit. Rev. Then Drug Carrier Syst. 5: 21-67
9. Hendeles, L., lafrate, P. R., Weinberger, M. (1984) A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products. Clin. Pharmacokin. 9: 95-135
10. Jacobs, C. (1980) The role of cisplatin in the treatment of recurrent head and neck cancer. In: Prestayko A. W., Crooke S. T., Carter S. K. (eds) Cisplatin. Current Status and New Developments. Academic Press, New York, pp 423-432
11. Loehrer, P. J., Einhorn, L. H. (1984) Cisplatin. Ann. Int. Med. 100: 704-713
12. Los, G., Verdegaal, E., Noteborn, H. P. J. M., Ruevekamp, M, Graeff, A. D., Meesters, E. W, Huinink, D. T. B., McVie, J. G. (1991) Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochem. Pharmacol. 42: 357-363
13. Marina, N. M., Rodman, J., Shema, S. J., Bowman, L. C., Douglass, E., Furman, W., Santana, V. M., Hudson, M., Williams, J., Meyer, W, Madden, T., Pratt, C. (1993) Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J. Clin. Oncol. 11: 554-560
14. Matharu, R. S., Sanghavi, N. M. (1992) Novel drug delivery system for captopril. Drug Dev. Ind. Pharm. 18: 1567-1574
15. Mortazavi, S. A., Smart J. D. (1994) An in-vitro method for assessing the duration of mucoadhesion. J. Contr. Rel. 31: 207-212
16. Muggia, F. M. (1989) Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin. Oncol. 16 (Suppl.): 7-13
17. Muggia F. M. (1991) Cisplatin update. Semin. Oncol. 18: 1-4
18. Niwa, K., Takaya, T., Morimoto, T., Takada, K. (1995) Preparation and evaluation of a time-controlled release capsule made of ethylcellulose for colon delivery of drugs. J. Drug Target. 3: 83-89
19. Offerman, J. J., Meijer, S., Sleijfer, D. T., Mulder, N. H., Donker, A. J. M., Schraffordt Koops, H., van der Hem, G. K. (1984) Acute effect of cis-diamminedichloroplatinum (CDDP) on renal function. Cancer Chemother. Pharmacol. 12: 36-38
20. Perry, M. C., Green, M. R., Mick, R., Schein, P. (1986) Cisplatin in patients with gastric cancer. A cancer and leukemia group B phase II study. Cancer Treat. Rep. 70: 415-416
21. Pinzani, V (1994) Cisplatin-induced renal toxicity and toxicitymodulating strategies: a review. Cancer Chemother. Pharmacol. 35: 1-9
22. Ruckdeschel, J. C. (1994) The future role of cisplatin. Sem. Oncol. 21 (Suppl.) 12: 114-118
23. Sautner, T., Hofbauer, F., Depish, D., Schiessel, R., Jakesz, R. (1994) Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J. Clin. Oncol. 12: 970-974
24. Seymour, L. W., Duncan, R., Duffy, J., Ng, S. Y., Heller, J. (1994) Poly(ortho ester)matrices for controlled release of the antitumour agent 5-fluorouracil. J. Contr. Rel. 31: 201-206
25. Smart, J. D. (1992) Some formulation factors influencing the rate of drug release from bioadhesive matrices. Drug Dev. Ind. Pharm. 18: 223-232
26. Takaya, T., Ikeda, C., Imagawa, N., Niwa, K., Takada, K. (1995) Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs. J. Pharm. Pharmacol. 47:474-478
27. Yoshikawa, Y, Ohta, S., Takada, K. (1995) A computer program for the analysis of chromatograms used in pharmacokinetic studies. Int. J. Bio-Med. Comput. 38: 269-276